These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 2878798)

  • 1. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Heel RC; Lewis SP
    Drugs; 1986 Dec; 32(6):481-508. PubMed ID: 2878798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine: prescribing guidelines for the newest antidepressant.
    Pary R; Tobias C; Lippmann S
    South Med J; 1989 Aug; 82(8):1005-9. PubMed ID: 2669150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Milne RJ; Goa KL
    Drugs; 1991 Mar; 41(3):450-77. PubMed ID: 1711447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.
    Heel RC; Morley PA; Brogden RN; Carmine AA; Speight TM; Avery GS
    Drugs; 1982 Sep; 24(3):169-206. PubMed ID: 6215240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine tenth anniversary update: the progress continues.
    Stokes PE; Holtz A
    Clin Ther; 1997; 19(5):1135-250. PubMed ID: 9385500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.
    Byerley WF; Reimherr FW; Wood DR; Grosser BI
    J Clin Psychopharmacol; 1988 Apr; 8(2):112-5. PubMed ID: 3286684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Ward A
    Drugs; 1986 Oct; 32(4):313-34. PubMed ID: 3096686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tianeptine: a review of its use in depressive disorders.
    Wagstaff AJ; Ormrod D; Spencer CM
    CNS Drugs; 2001; 15(3):231-59. PubMed ID: 11463130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of antidepressants.
    Kasper S; Fuger J; Möller HJ
    Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine: a serotonin-specific, second-generation antidepressant.
    Sommi RW; Crismon ML; Bowden CL
    Pharmacotherapy; 1987; 7(1):1-15. PubMed ID: 3554156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.
    Feighner JP; Cohn JB
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):20-5. PubMed ID: 3882676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.
    Feighner JP
    J Clin Psychiatry; 1985 Sep; 46(9):369-72. PubMed ID: 3897204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
    Stark P; Hardison CD
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):53-8. PubMed ID: 3882682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants.
    Pacher P; Ungvari Z; Kecskemeti V; Furst S
    Curr Med Chem; 1998 Oct; 5(5):381-90. PubMed ID: 9756980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.